Genotype 2 hepatitis C virus is one of the six main genotypes of the hepatitis C virus (HCV). Basically, a hepatitis C genotype is simply a certain type of the disease. In the United States, genotype 1 is the most common hepatitis C genotype.

Genotype 2 hepatitis C causes symptoms that are basically the same as those associated with other hepatitis C genotypes. It is also contracted in the same ways — by coming into contact with contaminated blood like in blood transfusions. However, genotype 2 hepatitis C, along with genotype 3, is generally easier to treat than genotype 1.

Genotype 2 hepatitis C is typically treated with two drugs: interferon and ribavirin. Interferon is administered via injection, usually three times per week. Ribavirin is taken in pill form, usually twice daily. Together, the two drugs make up the usual combination treatment for hepatitis C.

Unfortunately, the drugs used to treat genotype 2 hepatitis C, as well as other hepatitis C genotypes, can cause side effects. Patients may experience flu-like symptoms and low red or white blood cell counts. Irritability and depression may occur as well.

Hepatitis C treatment generally lasts for about six to 12 months. The length of time required for treatment depends, in part, on which genotype the individual is battling. Following treatment, about 60% of genotype 1 patients still have detectable viral loads. If a person has a detectable viral load, this means that the amount of virus in the blood is enough for a test to detect. Only about 20% of genotype 2 patients still have detectable virus loads after treatment.

If a person with hepatitis C has a detectable viral load following treatment, he or she will likely have to continue using interferon. This is often referred to as maintenance therapy. In such cases, interferon is typically taken at doses that are much lower than those used in initial treatment.

Several factors influence the success of hepatitis C treatment. Individuals with genotype 2 or 3 hepatitis C tend to fare better. Likewise, individuals with lower viral loads and little to no liver damage respond more favorably to treatment. Women, individuals under 40 years of age, and those who abstain from alcohol experience treatment success more frequently as well.